AstraZeneca
Korea's IMBDx Explores NSCLC Therapy Guidance, Multi-Cancer Early Detection for Liquid Biopsy Tech
Premium
The company recently published data on its NGS-based pleural effusion liquid biopsy panel and is launching a large multimodal MCED study in Korea.
FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Ultralow Breast Cancer Patients
The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.
AstraZeneca to Use Tracer Biotechnologies Cancer Monitoring Tech for Clinical Trials
Tracer has developed a proprietary platform for tumor-informed circulating-tumor DNA detection using digital PCR.
Owkin, AstraZeneca Partner to Develop AI-Based Breast Cancer Prescreening Tool
The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.
Pillar Biosciences, AstraZeneca Partner on Liquid Biopsy Testing in Europe
AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.